- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Seattle Genetics Inc
Add to PortfolioSGEN:US
20.5700 USD 0.0800 0.39%As of 20:10:00 ET on 05/25/2012.
Snapshot for Seattle Genetics Inc (SGEN)
| Open: | 20.5100 | Day's Range: | 20.3100 - 20.7800 | Volume: | 620,466 | Bid: | 20.5700 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 20.6500 | 52wk Range: | 12.2900 - 22.4000 | 1-Yr Rtn: | +5.38% | Ask: | 20.5800 |
Key Statistics for SGEN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -1.1500 |
| Est. EPS (USD) (12/2012) | -0.5220 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 2,407.75 |
| Shares Outstanding (M) | 117.05 |
| Enterprise Value (M USD) (ttm) | 2,098.88 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 10.9112 |
| Price/Sale (ttm) | 18.1365 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/03/2012 |
More SGEN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for SGEN
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for SGEN
Seattle Genetics, Inc. discovers and develops monoclonal antibody-based drugs to treat cancer and related diseases. The Company's technologies increase the potency and efficacy of monoclonal antibodies with specificity for cancer.
| Clay B SiegallChairman/Pres/CEO/Co-Founder | Todd E SimpsonChief Financial Officer |
| Eric L DobmeierChief Operating Officer | Thomas C ReynoldsChief Medical Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page